Palisade Bio (NASDAQ:PALI) Insider Mitchell Lawrence Jones Sells 51,880 Shares

Palisade Bio, Inc. (NASDAQ:PALI) insider Mitchell Lawrence Jones sold 51,880 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the transaction, the insider owned 94,009 shares in the company, valued at approximately $192,718.45. The trade was a 35.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Palisade Bio Trading Down 1.4%

Palisade Bio stock opened at $2.05 on Thursday. The firm has a market capitalization of $355.84 million, a price-to-earnings ratio of -2.03 and a beta of 1.50. The firm’s fifty day moving average price is $1.92 and its two-hundred day moving average price is $1.92. Palisade Bio, Inc. has a 1-year low of $0.53 and a 1-year high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, research analysts forecast that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PALI. Oppenheimer set a $7.00 target price on Palisade Bio in a report on Tuesday, June 30th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Finally, Wolfe Research initiated coverage on shares of Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $8.83.

Key Stories Impacting Palisade Bio

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: Director Robert Jr. Baltera bought 30,000 shares at about $2.03 per share, following earlier purchases of 20,000 shares and 10,000 shares at $1.98. Repeated insider buying can signal confidence in Palisade Bio’s outlook. SEC filing
• Positive Sentiment: Analysts remain broadly constructive on Palisade Bio, with recent ratings including a “strong-buy” upgrade and multiple buy ratings, plus a consensus price target well above the current trading range. MarketBeat PALI page
• Neutral Sentiment: CEO John David Finley sold 146,798 shares, but the filing says the transaction was to cover tax withholding obligations tied to vesting equity awards, which makes the sale less concerning than a discretionary insider exit. SEC filing
• Neutral Sentiment: Insider Mitchell Lawrence Jones also sold shares for the same tax-withholding reason, adding to the day’s mixed insider activity. SEC filing

Hedge Funds Weigh In On Palisade Bio

Institutional investors have recently modified their holdings of the business. Total Clarity Wealth Management Inc. bought a new stake in Palisade Bio during the fourth quarter worth $70,000. Jefferies Financial Group Inc. bought a new position in Palisade Bio during the fourth quarter valued at about $110,000. Geode Capital Management LLC increased its holdings in Palisade Bio by 5,780.7% during the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock worth $3,681,000 after buying an additional 1,538,832 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Palisade Bio during the fourth quarter worth about $1,310,000. Finally, TD Asset Management Inc bought a new stake in Palisade Bio in the fourth quarter worth about $480,000. 11.79% of the stock is owned by institutional investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.